NCT04305041 2025-08-29
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Completed
Clinical Trials
6 trialsNCT03200847 2024-10-01
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
University of Colorado, Denver
Phase 1/2 Completed
NCT02842827 2023-07-11
IMG-7289-CTP-101
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 1/2 Completed
NCT02751255 2023-04-28
DARA/ATRA
Amsterdam UMC, location VUmc
Phase 1/2 Completed
NCT00175812 2015-06-24
Differentiation Induction in Acute Myelogenous Leukemia
University of Bergen
Phase 1/2 Completed
NCT00995332 2015-06-24
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
University of Bergen
Phase 1/2 Completed